Pharmacokinetics and metabolism update for some recent antipsychotics

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 7, 2011, Pages 829-846

  Caccia, Silvio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

active metabolites; aripiprazole; cariprazine; drug interactions; lurasidone; metabolic pathways; perospirone; pharmacokinetics

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CARIPRAZINE; CYTOCHROME P450 3A4; DEHYDROARIPIPRAZOLE; DILTIAZEM; ETOPERIDONE; HYDROXYPEROSPIRONE; ILOPERIDONE; ITRACONAZOLE; KETOCONAZOLE; LURASIDONE; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PEROSPIRONE; QUETIAPINE; RESPERIDONE; RIFAMPICIN; RISPERIDONE; TANDOSPIRONE; TRAZODONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ABDOMINAL PAIN; ATRIOVENTRICULAR BLOCK; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG STRUCTURE; DRUG UPTAKE; HUMAN; NONHUMAN; PHARMACOKINETICS; PHENOTYPE; PSYCHOTHERAPY; QT PROLONGATION; RECEPTOR BINDING; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SINGLE DRUG DOSE; STEADY STATE;

ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG INTERACTIONS; HUMANS; ISOINDOLES; METABOLIC DETOXICATION, DRUG; PIPERAZINES; QUINOLONES; THIAZOLES;

EID: 79959241843     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.575061     Document Type: Review

References (104)

1. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Pysichiatry 2003;27(7):1159-72 (Pubitemid 37464960)
2. Kapur S, Agid O, Mizrahi R, Li M. How antipsychotics work-from receptors to reality. Neurorx 2006;3(1):10-21 (Pubitemid 43276632)
3. Barnes TR, Mcphillips MA. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry 1999;38 (Suppl):34-43 (Pubitemid 29230048)
4. Huttunen M. The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol 1995;15(Suppl 1):4S-10S
5. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28(3):519-26
6. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005;19(6 Suppl):16-27 (Pubitemid 44567855)
7. Dorado P, Berecz R, Penas-Lledo EM, Llerena A. Antipsychotic drugs and Qtc prolongation: the potential role of cyp2d6 genetic polymorphism. Expert Opin Drug Metab Toxicol 2007;3(1):9-19 (Pubitemid 47315416)
8. Lieberman JA, Stroup TS, McEvoy JP, et al.; For the clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
9. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 2006;63(10):1079-87 (Pubitemid 44498387)
10. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 2009;23(8):649-59
11. Foussias G, Remington G. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. Can J Psychiatry 2010;55(3):117-25
12. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64(15):1715-36 An overview of the profile of aripiprazole.
13. Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 2007;32(1):67-77 (Pubitemid 44967785)
14. Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 2010;16(5):488-501 This reviews summarizes the neuropharmacological profiles of the current antipsychotics, with emphasis on potential mechanisms of third generation antipsychotics.
15. Jones CA, McCreary AC. Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology 2008;55(6):1056-65
16. Terry AV Jr, Buccafusco JJ, Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res 2008;195(1):30-8
17. Meltzer HY, Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res 2008;195(1):98-102
18. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006;2:CD004578
19. Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2008;3:CD006617
20. Kato T, Hirose A, Ohno Y, et al. Binding profile of SM-9018, a novel antipsychotic candidate. Jpn J Pharmacol 1990;54(4):478-81
21. Shiwa T, Amano T, Matsubayashi H, et al. Perospirone, a novel antipsychotic agent, hyperpolarizes rat dorsal raphe neurons via 5-HT1A receptor. J Pharmacol Sci 2003;93:114-17 (Pubitemid 37254275)
22. Araki T, Yamasue H, Sumiyoshi T, et al. Perospirone in the treatment of schizophrenia: effect on verbal memory organization. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(2):204-8 (Pubitemid 43288059)
23. de Paulis T. Perospirone (Sumitomo Pharmaceuticals). Curr Opin Investig Drugs 2002;3(1):121-9
24. Onrust SV, McClellan K. Perospirone. CNS Drugs 2001;15(4):329-37 The first overview of the profile of perospirone.
25. Okugawa G, Kato M, Wakeno M, et al. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci 2009;63(3):322-8
26. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010;334(1):171-81
27. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(6):829-36
28. Loebel A, Cucchiaro J, Ogasa M, et al. Efficacy of lurasidone: summary of results from the clinical development program. Int J Neuropsychopharmacol 2010;70(6):227-8
29. Harwey PD, Murasaki M, Cucchiaro J, et al. A three arm dose finding study of lurasidone; efficacy and tolerability data. Schizophr Res 2010;117:2-3 (374-375)
30. Cucchiaro J, Pikalow A, Ogasa M, et al. Safety of lurasidone: pooled analysis of five placebo-controlled trials in patients with schizophrenia. Int J Neuropsychopharmacol 2010;13(Suppl. S1):abstract P-20.021, 217
31. Bose A, Li D, Migliore R, et al. The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. Int J Neuropsychopharmacol 2010;abstract P-04.012, 88
32. Knesevich MA, Papadakis K, Bose A, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord 2009;11:s1 (54)
33. Kiss B, Horvath A, Nemethy Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 2010;333(1):328-40
34. Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 2007;8(7):539-54 (Pubitemid 47016322)
35. Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs 2010;11(7):802-12 Reviews the rationale underlying the development of antipsychotics that combine antagonism or partial agonism at dopamine D2-receptors with agonism at serotonin 5-HT1A receptors.
36. Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther 2010;32(Suppl 1):S3-20
37. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009;18(11):1715-26 The first overview of the profile of lurasidone.
38. Grunder G. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr Opin Investig Drugs 2010;11(7):823-32 The first overview of the profile of cariprazine.
39. Food and Drug Administration. Drug Approval Package. Latuda (lurasidone hydrochloride) Tablets. Sunovion Pharmaceuticals, Inc. Clinical Review; Pharmacology Review(s); Clinical Pharmacology Biopharmaceutics Review(s). Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search. Drug-Details [Last accessed November 2010]
40. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996;57(Suppl 11):12-25 (Pubitemid 26389782)
41. Sheehan JJ, Sliwa JK, Amatniek JC, et al. Atypical antipsychotic metabolism and excretion. Curr Drug Metab 2010;11(6):516-25
42. Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 2000;38(5):393-414 (Pubitemid 30265260)
43. Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 2000;22(1):118-21 (Pubitemid 30083111)
44. Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 2006;58(7):871-85 (Pubitemid 43967103)
45. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008;9(5):410-18
46. Latuda (lurasidone HCl) (Prescribing Information). Sunovion Pharmaceutical, Inc. Available from: http://latuda.com/ latudaprescribinginformation.pdf. [Last accessed November 2010]
47. Boulton DW, Kollia G, Mallikaarjun S, et al. Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clin Pharmacokinet 2008;47(7):475-85 (Pubitemid 351861959)
48. Yasui-Furukori N, Inoue Y, Tateishi T. Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2003;789(2):239-45 (Pubitemid 36549193)
49. Yasui-Furukori N, Furukori H, Nakagami T, et al. Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit 2004;26(4):361-5 (Pubitemid 38989654)
50. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. Clin Pharmacol 2004;44(2):179-87 (Pubitemid 38114317)
51. Yokoi F, Grunder G, Biziere K, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology 2002;27(2):248-59 (Pubitemid 34692591)
52. Mamo D, Graff A, Mizrahi R, et al. Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: a triple tracer pet study. Am J Psychiatry 2007;164:1411-17 (Pubitemid 47461142)
53. McEvoy JP, Daniel DG, Carson WH Jr, et al. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007;41(11):895-905 (Pubitemid 47260697)
54. Sekine Y, Ouchi Y, Takei N, et al. Perospirone is a new generation antipsychotic: evidence from a positron emission tomography study of serotonin 2 and D2 receptor occupancy in the living human brain. J Clin Psychopharmacol 2006;26(5):531-3 (Pubitemid 44401481)
55. Arakawa R, Ito H, Takano A, et al. Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects. Psychopharmacology (Berl) 2010;209(4):285-90
56. Abilify (Aripiprazole) Tablets: Otsuka Pharmaceutical Co., Ltd. Drug Approval Package.Application no.: 21-436 Clinical Pharmacology Biopharmaceutics Review (S). Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2002/21-436-abilify.cfm. [Last accessed 4 November 2010]
57. Caccia S. N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed. Curr Drug Metab 2007;8(6):612-22 (Pubitemid 47209098)
58. Kirschner N, Gemesi LI, Vastag M, et al. In vitro metabolismo of RGH-188. Drug Metab Rev 2008;40:abstract 182
59. Meszaros GP, Kapas M, Borsos M, et al. Pharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic candidate. Eur Neuropsychopharmacol 2007;217(Suppl 4):abstract p.3.c.0.47
60. Meszaros GP, Agai-Csongor E, Kapas M. Sensitive lc-ms/ms methods for the quantification of rgh-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine. J Pharm Biomed Anal 2008;48(2):388-97
61. Masui T, Kusumi I, Takahashi Y, Koyama T. Effect of carbamazepine on the single oral dose pharmacokinetics of perospirone and its active metabolite. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(7):1330-3
62. Kusumi I, Masui T, Koyama T. Long-term perospirone treatment with a single dose at bedtime in schizophrenia: relevant to intermittent dopamine D2 receptor antagonism. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(2):520-2 (Pubitemid 351178971)
63. Suzuki Y, Sawamura K, Ono S, et al. The wide variability of perospirone metabolism and the effect of perospirone on prolactin in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(6):830-3
64. Mizuno Y, Tani N, Komuro S, et al. In vitro metabolism of perospirone in rat, monkey and human liver microsomes. Eur J Drug Metab Pharmacokinet 2003;28(1):59-65
65. Kitamura A, Mizuno Y, Natsui K, et al. Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone. Biopharm Drug Dispos 2005;26(2):59-65 (Pubitemid 40403158)
66. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003;60:974-7 (Pubitemid 37222078)
67. Grunder G, Fellows C, Janouschek H, et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18f]fallypride pet study. Am J Psychiatry 2008;165(8):988-95
68. Kirschbaum KM, Muller MJ, Malevani J, et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response, and side effects. World J Biol Psychiatry 2008;9(3):212-8
69. Molden E, Lunde H, Lunder N, Refsum H. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006;28(6):744-9 (Pubitemid 44967653)
70. Kirschbaum M, Uhr M, Holthoewer D, et al. Pharmacokinetics of acute and sub-chronic aripiprazole in p-glycoprotein deficient mice. Neuropharmacology 2010;59(6):474-9
71. Wood MD, Scott C, Clarke K, et al. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol 2006;546(1-3):88-94 (Pubitemid 44339632)
72. Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet 2005;20:55-64
73. Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2006;2(2):171-82 (Pubitemid 46372363)
74. Loovers HM, Van Der Weide J. Implementation of CYP2D6 genotyping in psychiatry. Expert Opin Drug Metab Toxicol 2009;5(9):1065-77
75. Sparshatt A, Taylor D, Patel MX, Kapur S. A systematic review of aripiprazole - dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry 2010;71(11):1447-56
76. Takahashi Y, Kusumi I, Ishikane T, Koyama T. In vivo occupation of dopamine D1, D2 and serotonin 2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain. J Neural Transm 1998;105(2-3):181-91
77. Masui T, Kusumi I, Takahashi Y, Koyama T. Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone. Ther Drug Monit 2006;28(1):73-5 (Pubitemid 44391697)
78. Aripiprazole/Abilify (Prescribing Information). Bristol-Myers Squibb, Otsuka Pharmaceutical America, Inc. Rev November 2009. Available from: http://www.abilify.com. [Last accessed October 2010]
79. Kim JR, Seo HB, Cho JY, et al. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Br J Clin Pharmacol 2008;66(6):802-10
80. Chiu Y, Nielsen J, Sarrubi D, Kowalski K. Population pharmacokinetics of lurasidone in healthy subjects and subjects with schizophrenia [abstract 1729]. Annual meeting of the population approach group in Europe; 2010. p. 19. Available from: www.page-meeting.org/?
81. Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf 2006;29(7):587-98
82. Thyssen A, Vermeulen A, Fuseau E, et al. Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. Clin Pharmacokinet 2010;49(7):465-78
83. Gareri P, De Fazio P, De Fazio S, et al. Adverse effects of atypical antipsychotics in the elderly: a review. Drugs Aging 2006;23(12):937-56 (Pubitemid 44936061)
84. Greenaway M, Elbe D. Focus on aripiprazole: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2009;18(3):250-60
85. Blankenship K, Erickson CA, Stigler KA, et al. Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6-17 years. Pediatr Health 2010;4(4):375-81
86. Findling RL, Kauffman RE, Sallee FR, et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J Clin Psychopharmacol 2008;28(4):441-6
87. Bachmann CJ, Rieger-Gies A, Heinzel-Gutenbrunner M, et al. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Ther Drug Monit 2008;30(4):462-6
88. Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005;1(3):447-71
89. Pichini S, Papaseit E, Joya X, et al. Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics. Ther Drug Monit 2009;31(3):283-318
90. Caccia S, Clavenna A, Bonati M. Antipsychotic drug toxicology in children. Expert Opin Drug Metab Toxicol 15 March 2011 [Epub ahead of print]
91. Mallikaarjun S, Shoaf SE, Boulton DW, Bramer SL. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Clin Pharmacokinet 2008;47(8):533-42 (Pubitemid 351969827)
92. Kubo M, Koue T, Maune H, et al. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 2007;22(5):358-66
93. Hendset M, Hermann M, Lunde H, et al. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 2007;63(12):1147-51 (Pubitemid 350112762)
94. Castberg I, Spigset O. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry 2007;40(3):107-10 (Pubitemid 46910381)
95. Waade RB, Christensen H, Rudberg I, et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit 2009;31(2):233-8
96. Shimakura J, Tani N, Mizuno Y, et al. In vitro drug-drug interactions with perospirone and concomitantly administered drugs in human liver microsomes. Eur J Drug Metab Pharmacokinet 2003;28(1):67-72
97. Wang JS, Zhu HJ, Donovan JL, et al. Aripiprazole brain concentration is altered in p-glycoprotein deficient mice. Schizophr Res 2009;110:90-4
98. Boulton D, Devane C, Liston H, Markowitz J. In vitro p-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002;71(2):163-9
99. Zhou YG, Li KY, Li HD. Effect of the novel antipsychotic drug perospirone on p-glycoprotein function and expression in caco-2 cells. Eur J Clin Pharmacol 2008;64(7):697-703
100. Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Ther 2009;26(8):739-48
101. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46(5):359-88 (Pubitemid 46686464)
102. Muscatello MR, Bruno A, Pandolfo G, et al. Emerging treatments in the management of schizophrenia - focus on sertindole. Drug Des Devel Ther 2010;4:187-201
103. Caccia S, Pasina L, Nobili A. New atypical antipsychotics for schizophrenia: iloperidone. Drug Des Devel Ther 2010;4:33-48
104. De Leon J, Sandson NB, Cozza KL. Apreliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II. Psychosomatics 2008;49(4):347-61 (Pubitemid 351905210)